SEQUENCE LISTING

<110> LO, YUK-MING DENNIS WAINSCOAT, JAMES STEPHEN	
<120> NON-INVASIVE PRENATAL DIAGNOSIS	
<130> JAK-PT001	
<140> US 09/380,696 <141> 1999-11-29	
<150> GB9621367.3 <151> 1997-03-04	
<160> 11	
<170> WordPad	
<210> 1 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> GeneAmp DNA Amplification Primer Y1.7	
<400> 1 catccagage gteectgget t	21
<210> 2 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> GeneAmp DNA Amplification Primer Y1.8	
<400> 2 ctttccacag ccacatttgt c	21
<210> 3 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> TaqMan Amplification Primer SRY-109F	
<400> 3 tggcgattaa gtcaaattcg c	21
<210> 4 <211> 25 <212> DNA <213> Artificial Sequence	

<220> <223> TaqMan Amplification Primer SRY-245R	
<400> 4 ccccctagta ccctgacaat gtatt	25
<210> 5 <211> 26 <212> DNA <213> Artificial Sequence	
<220> <223> Dual Labeled Fluorescent TaqMan Probe SRY-142T	
<400> 5 agcagtagag cactcaggga ggcaga	26
<210> 6 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> RhD TaqMan Amplification Primer RD-A	
<400> 6 cctctcactg ttgcctgcat t	21
<210> 7 <211> 18 <212> DNA <213> Artificial Sequence	
<220> <223> RhD TaqMan Amplification Primer RD-B	
<400> 7 agtgcctgcg cgaccatt	18
<210> 8 <211> 31 <212> DNA <213> Artificial Sequence	
<220> <223> Dual Labelled Fluorescent TaqMan Probe RD-T	
<400> 8 tacgtgagaa acgctcatga cagcaaagtc t	31
<210> 9 <211> 22 <212> DNA <213> Artificial Sequence	
<220>	

TaqMan	Amplification	Primer	beta-globir	1-354F		
9						
cctga ct	cctgagga ga					22
10						
21						
DNA						
Artific	ial Sequence					
TaqMan	Amplification	Primer	beta-globir	1-455R		
10						
atacc aa	cctgccca g					21
17						
DNA						
Artific	cial Sequence					
Dual La	belled Fluores	cent Ta	ıqMan Probe	beta-glo	bin-402T	
11						
	gatgaagt tggtg	ia				26
	9 cctga ct 10 21 DNA Artific TaqMan 10 atacc aa 11 26 DNA Artific	9 cctga ctcctgagga ga 10 21 DNA Artificial Sequence TaqMan Amplification 10 atacc aacctgccca g 11 26 DNA Artificial Sequence Dual Labelled Fluores 11	9 cctga ctcctgagga ga 10 21 DNA Artificial Sequence TaqMan Amplification Primer 10 atacc aacctgccca g 11 26 DNA Artificial Sequence Dual Labelled Fluorescent Ta	9 cctga ctcctgagga ga 10 21 DNA Artificial Sequence TaqMan Amplification Primer beta-globin 10 atacc aacctgccca g 11 26 DNA Artificial Sequence Dual Labelled Fluorescent TaqMan Probe	10 21 DNA Artificial Sequence TaqMan Amplification Primer beta-globin-455R 10 atacc aacctgccca g 11 26 DNA Artificial Sequence Dual Labelled Fluorescent TaqMan Probe beta-glo	9 cctga ctcctgagga ga 10 21 DNA Artificial Sequence TaqMan Amplification Primer beta-globin-455R 10 atacc aacctgccca g 11 26 DNA Artificial Sequence Dual Labelled Fluorescent TaqMan Probe beta-globin-402T 11

Volpe and Koenig, P.C. Revision of PTO/SB/17 (11-00)(7)

Approved for use through 10/31/2002. OMB 0651-00320

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 583.00

Complete if Known		
Application Number	Not Yet Known	
Filing Date	Not Yet Known	
First Named Inventor	Lo et al.	
Examiner Name	Not Yet Known	
Group Art Unit	Not Yet Known	
Attorney Docket No.	JAK-PT001.1	

METHOD OF PAYMENT	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES			
Deposit Deposit	Large Small Entity Entity			
Account Number 22-0493	Fee Fee Fee Fee Fee Description F	ee Paid		
Deposit Value and Kannin D.C.	Code (\$) Code (\$)			
Account Name Volpe and Koenig, P.C.	105 130 205 65 Surcharge - late filing fee or oath			
Charge Any Deficiency or Credit any Overpayment in the Total Fees Associated with this Communication	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Applicant claims small entity status	139 130 139 130 Non-English specification			
See 37 CFR 1 27	147 2,520 147 2,520 For filing a request for ex parte reexamination			
2. X Payment Enclosed: X Check Credit card Money Cother	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month			
Large Entity Small Entity	116 390 216 195 Extension for reply within second month			
Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month			
(4)	118 1,390 218 695 Extension for reply within fourth month			
101 710 201 355 Utility filing fee 355.00	128 1,890 228 945 Extension for reply within fifth month			
107 490 207 245 Plant filing fee	119 310 219 155 Notice of Appeal			
108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal			
114 150 214 75 Provisional filing fee	121 270 221 135 Request for oral hearing			
(IN) OFF 00	138 1,510 138 1,510 Petition to institute a public use proceeding			
SUBTOTAL (1) (\$)355.00	140 110 240 55 Petition to revive - unavoidable			
2. EXTRA CLAIM FEES Fee from	141 1,240 241 620 Petition to revive - unintentional			
Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)			
Total Claims 32 - 20 ** 12 x 9.00 = 108.00	143 440 243 220 Design issue fee			
Independent 6 - 3 ** 3 × 40.00 = 120.00	144 600 244 300 Plant issue fee	——— i		
Multiple Dependent 0 = 0	122 130 122 130 Petitions to the Commissioner			
Laura Partita Daniel	123 50 123 50 Processing fee under 37 CFR 1 17(q)			
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)			
102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection			
104 270 204 135 Multiple dependent claim, if not paid	(37 CFR § 1.129(a))			
109 80 209 40 ** Reissue independent claims over onginal patent	149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))			
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)			
and over original patent	169 900 169 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$)228.00	Other fee (specify)			
. ,	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0			
**or number previously paid, if greater; For Reissues, see above	SUBTUIAL (3)			

SUBMITTED BY			Complete (if applicable)		
Name (Pnnt/Type)	C. Frederick Koenig III, Esquire	Registration No. (Atterney/Agent)	29,662	Telephone	215-568-6400
Signature	15 9	9		Date	June 1, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.